论文部分内容阅读
本刊讯江苏丰山集团股份有限公司(以下简称“丰山集团”)近期在证监会网站披露招股说明书,公司拟在上交所公开发行不超过2000万股,发行后总股本不低于8000万股,保荐机构为华泰联合证券。丰山集团本次IPO计划募集资金5.75亿元,用于年产1500吨硝磺草酮原药生产线技改等四大项目。本次募投项目拟生产产品为7种,其中,精喹禾灵为丰山集团现有优势产
Company News Jiangsu Fengshan Group Co., Ltd. (hereinafter referred to as “Fengshan Group”) disclosure prospectus recently in the CSRC website, the company intends to open no more than 20 million shares in the Shanghai Stock Exchange, after the issue of the total share capital of not less than 8000 Million shares, the sponsor for Huatai Securities. Fengshan Group IPO plans to raise funds 575 million yuan for the annual output of 1500 tons of mesotrione original drug production line technology transformation and other four major projects. The investment projects to be raised to produce seven kinds of products, of which Quizalofop is Fengshan Group existing advantages of production